2019 Methodology for Heart House Roundtables: A Report of the American College of Cardiology Solution Set Oversight Committee

Many of these new pharmacological therapies are costly and prior authorization may be required by payers prior to prescribing these agents. [...]the College convened a roundtable focused on 1) strategies to facilitate effective prior authorization of novel and emerging therapies; and 2) identification of high-risk patients who are appropriate candidates for these therapies. Figure 5 provides an overview of the firewall specifications preventing involvement in roundtable planning by industry supporters. Because the ACC adheres to a very strict conflict of interest policy to prevent any influence by financial supporters, all travel and food for participants is paid for directly by the ACC and is not associated with any industry funding. [...]participants are not subject to reporting under the Physician Payments Sunshine Act or disclosure of relationships with industry in the ACC’s database. [...]the ACC developed and published an Expert Consensus Decision Pathway on Periprocedural Management of Anticoagulation in Patients with Atrial Fibrillation (50).